Clinical Trial Update: Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk [Phase 2]

View source ↗

Summary

Phase 2 results have been posted for a growth hormone releasing hormone analog aimed at improving non-alcoholic fatty liver disease and associated cardiovascula…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease
• Obesity

Drugs mentioned

• Growth Hormone Releasing Hormone analog

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Non-Alcoholic Fatty Liver Disease, Obesity | Phase 2 | Status: COMPLETED | Results posted: 2025-11-20